Generic medicine pricing policies in Europe: Current status and impact

Pharmaceuticals

Volumn 3, Issue 3, 2010, Pages 471-481

  Dylst, Pieter ^a   Simoens, Steven ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Europe; Generic medicines; Pharmaceutical policy; Pricing

Indexed keywords

GENERIC DRUG; SIMVASTATIN;

AMBULATORY CARE; DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; ECONOMIC ASPECT; EUROPE; HEALTH CARE POLICY; HEALTH INSURANCE; REVIEW;

EID: 77950435775     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3030471     Document Type: Review

References (24)

1. Grootendorst, P.; Pierard, E.; Shim, M. Life-expectancy gains from pharmaceutical drugs: A critical appraisal of the literature. Expert Rev. Pharmacoecon. Outcomes Res. 2009, 9, 353-364.
2. Organisation for Economic Co-operation and Development. Health at a glance 2007; Organisation for Economic Co-operation and Development: Paris, France, 2007.
3. Crown, W.H.; Ling, D.; Berndt, E. Measuring the costs and benefits of pharmaceutical expenditures. Expert Rev. Pharmacoecon. Outcomes Res. 2002, 2, 467-475.
4. Simoens, S.; De Coster, S. Sustaining generic medicines markets in Europe. Leuven: Katholieke Universiteit Leuven, 2006. Available at: www.egagenerics.com, accessed on 4 December 2009.
5. Kanavos, P. Do generics offer significant savings to the UK National Health Service? Curr. Med. Res. Opin. 2007, 23, 105-116.
6. IMS Health. Midas database; IMS Health: Brussels, Belgium, 2008.
7. Espin, J.; Rovira, J. Analysis of Differences and Commonalities in Pricing and Reimbursement Systems in Europe; DG Enterprise and Industry of the European Commission: Brussels, Belgium, 2007; http://ec.europa.eu/enterprise, accessed on 4 December 2009.
8. Simoens, S. Generic medicine pricing in Europe: Current issues and future perspective. J. Med. Econ. 2008, 11, 171-175.
9. European Generic Medicines Association. 2008 Market Review; European Generic Medicines Association: Brussels, Belgium, 2008.
10. Simoens, S. International comparison of generic medicine prices. Curr. Med. Res. Opin. 2007, 23, 2647-2654.
11. Magazzini, L.; Pammolli, F.; Riccaboni, M. Dynamic competition in pharmaceuticals. Patent expiry, generic penetration, and industry structure. Eur. J. Health Econom. 2004, 5, 175-182.
12. Martikainen, J.; Kivi, I.; Linnosmaa, I. European prices of newly launched reimbursable pharmaceuticals a pilot study. Health Pol. 2005, 74, 235-246.
13. Schulz, A. Evolving dynamics of US and European generics markets. J. Generic Med. 2004, 2, 23-32.
14. Danzon, P.M.; Chao, L.W. Cross-national price differences for pharmaceuticals: How large, and why? J. Health Econ. 2000, 19, 159-195.
15. Garattini, L.; Tediosi, F. A comparative analysis of generics markets in five European countries. Health Pol. 2000, 51, 149-162.
16. De Joncheere, K.; Rietveld, A.H.; Huttin, C. Experiences with generics. Int. J. Risk Safety Med. 2002, 15, 101-109.
17. Brekke, K.R.; Grasdal, A.L.; Holmås, T.H. Regulation and pricing of pharmaceuticals: Reference pricing or price cap regulation? Eur. Econ. Rev. 2009, 53, 170-185.
18. Puig-Junoy, J. A review of the impact of European pharmaceutical price regulation on generic price competition. PharmacoEconomics in press.
19. Bergman, M.A.; Rudholm, N. The relative importance of actual and potential competition: Empirical evidence from the pharmaceuticals market. J. Ind. Econ. 2003, 51, 455-467.
20. Ghislandi, S.; Krulichova, I.; Garattini, L. Pharmaceutical policy in Italy: Towards a structural change? Health Pol. 2005, 72, 53-63.
21. Kanavos, P.; Taylor, D. Pharmacy discounts on generic medicines in France: Is there room for further efficiency savings? Curr. Med. Res. Opin. 2007, 23, 2467-2476.
22. Leopold, C.; Habl, C.; Vogler, S. Tendering of Pharmaceuticals in EU Member States and EEA Countries. Results from the Country Survey; ÖBIG Forschungsund Planungsgesellschaft mbH: Vienna, Austria, 2008.
23. Arickx, F.; Bormans, V.; Leveque, F.; Mortier, M.; Soete, E.; Vanhaeren, E. Public Tendering for Off patent Medicines in Belgium-The Simvastatin Case; RIZIV: Brussels, Belgium, 2009.
24. Price Waterhouse Coopers. Ontario Public Drug Programs Competitive Agreement Initiative. Price Waterhouse Coopers: Ottawa, ON, Canada, 2007.